Paradigm Biopharmaceuticals

Paradigm Biopharma Webinar: Managing Director, Paul Rennie, speaks with the team at Sharewise to provide an overview of the clinical data and progress for iPPS in osteoarthritis.

Paradigm Biopharma is continuing to progress the regulatory review of its novel treatment for conditions including osteoarthritis and Mucopolysaccharidosis.

The company is developing an injectable iPPS treatment for diseases where inflammation plays a major pathogenic role.

The late stage drug development company is working towards a Phase 3 clinical trial of its iPPS treatment.

Osteoarthritis (OA) affects the quality of life of millions of people around the world, and for many there is no effective treatment. With PPS we are approaching OA from a completely different angle. We're shifting the paradigm.

Paradigm Founder and Managing Director, Paul Rennie, provides a Company overview and details exciting phase 2 clinical data produced by Paradigm as the Company prepares for the next stage of the phase 3 clinical program in knee osteoarthritis.

Paradigm Managing Director, Paul Rennie, speaks with Stockhead and outlines the 2023 Company highlights and the potential significant milestones ahead for Paradigm in 2024.

Paradigm Biopharmaceuticals is currently conducting a global, Phase 3 clinical trial for its iPPS treatment for osteoarthritis (OA).

In this interview, Paradigm Biopharmaceuticals Managing Director Paul Rennie discusses the potential for the company’s breakthrough treatment to break into the $8.28 billion global market for osteoarthritis therapeutics. 

Paradigm has cashed up, having raised $30.1 million in October last year to develop its iPPS treatment for the disease.